QHSLab is a small digital health company that sells a software platform to independent primary care practices — specifically, practices with one to ten providers. The platform helps these practices screen patients for behavioral health conditions like depression, anxiety, and suicide risk using digital questionnaires completed before or outside of visits. The platform scores assessments, generates reports, integrates with the practice's EHR, and continues to engage patients after visits through follow-up check-ins and asynchronous communication. The core value proposition is that the platform extends clinical reach beyond the office visit without adding significant staff burden, while also enabling practices to bill Medicare and commercial insurers for the supported clinical activities, generating additional revenue for the practice. QHSLab charges practices a recurring per-patient, per-month subscription fee, so revenue scales with the number of enrolled practices and active patients. QHSLab does not bill payers directly. QHSLab also operates AllergiEnd, a separate allergy diagnostics and treatment service that enables primary care practices to perform allergy skin testing in-office using FDA-cleared disposable applicators, bypassing referrals to specialists. Following a positive test, physicians can prescribe allergen immunotherapy via injections or sublingual drops sourced from third-party compounding pharmacies. QHSLab positions AllergiEnd as complementary to its digital platform, with both focused on managing chronic conditions at the primary care level. The company runs lean, with 12 full-time employees and contractors handling software development and marketing.